Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 9/2014

Open Access 01-09-2014 | Systematic Review

The Economic Burden of Head and Neck Cancer: A Systematic Literature Review

Authors: Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Talia Foster, Chris L. Pashos

Published in: PharmacoEconomics | Issue 9/2014

Login to get access

Abstract

Background

This systematic literature review aimed to evaluate and summarize the existing evidence on resource use and costs associated with the diagnosis and treatment of head and neck cancer (HNC) in adult patients, to better understand the currently available data. The costs associated with HNC are complex, as the disease involves multiple sites, and treatment may require a multidisciplinary medical team and different treatment modalities.

Methods

Databases (MEDLINE and Embase) were searched to identify studies published in English between October 2003 and October 2013 analyzing the economics of HNC in adult patients. Additional relevant publications were identified through manual searches of abstracts from recent conference proceedings.

Results

Of 606 studies initially identified, 77 met the inclusion criteria and were evaluated in the assessment. Most included studies were conducted in the USA. The vast majority of studies assessed direct costs of HNC, such as those associated with diagnosis and screening, radiotherapy, chemotherapy, surgery, side effects of treatment, and follow-up care. The costs of treatment far exceeded those for other aspects of care. There was considerable heterogeneity in the reporting of economic outcomes in the included studies; truly comparable cost data were sparse in the literature. Based on these limited data, in the US costs associated with systemic therapy were greater than costs for surgery or radiotherapy. However, this trend was not seen in Europe, where surgery incurred a higher cost than radiotherapy with or without chemotherapy.

Conclusions

Most studies investigating the direct healthcare costs of HNC have utilized US databases of claims to public and private payers. Data from these studies suggested that costs generally are higher for HNC patients with recurrent and/or metastatic disease, for patients undergoing surgery, and for those patients insured by private payers. Further work is needed, particularly in Europe and other regions outside the USA; prospective studies assessing the cost associated with HNC would allow for more systematic comparison of costs, and would provide valuable economic information to payers, providers, and patients
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
3.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013.
4.
5.
Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013;63(1):57–81.PubMedCrossRef
6.
Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009;115(5):922–35.PubMedCrossRef
7.
Chan AT, Gregoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii83–5.
8.
Crombie AK, Farah CS, Batstone MD. Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery. Br J Oral Maxillofac Surg. 2013.
9.
Amonkar MM, Chastek B, Samant N, Teitelbaum A. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population. J Med Econ. 2011;14(4):421–32.PubMed
10.
Anuradha V, Anand BB, Suresh AVS, Sinha S, Chinna Babu S, Suresh K. Palliative chemotherapy in head and neck squamous cell cancer—what is best in Indian population? A time without symptoms, treatment toxicity score based study. Indian J Med Paediatr Oncol. 2013;34(1):11–5.PubMedCentralPubMedCrossRef
11.
Arshad H, Ozer HG, Thatcher A, Old M, Ozer E, Agarwal A, et al. Intensive care unit versus non-intensive care unit postoperative management of head and neck free flaps: comparative effectiveness and cost comparisons. Head Neck. 2013.
12.
Bodard AG, Paris M, Salino S, Fortin T. Evaluation of two noninvasive repositioning systems for computer-assisted oral implant surgery in oral cancer patients. Int J Prosthodont. 2010;23(5):463–8.PubMed
13.
Braaksma M, van Agthoven M, Nijdam W, Uyl-de Groot C, Levendag P. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer. 2005;41(14):2102–11.PubMedCrossRef
14.
Brookes JT, Seikaly H, Diamond C, Mechor B, Harris JR. Prospective randomized trial comparing the effect of early suturing of tracheostomy sites on postoperative patient swallowing and rehabilitation. J Otolaryngol. 2006;35(2):77–82.PubMedCrossRef
15.
Chan JY, Semenov YR, Gourin CG. Postoperative urinary tract infection and short-term outcomes and costs in head and neck cancer surgery. Otolaryngol Head Neck Surg. 2013;148(4):602–10.PubMedCrossRef
16.
Chu CN, Muo CH, Chen SW, Lyu SY, Morisky DE. Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy. BMC Cancer. 2013;13:370.PubMedCentralPubMedCrossRef
17.
Cohen SM, Kim J, Roy N, Asche C, Courey M. The impact of laryngeal disorders on work-related dysfunction. Laryngoscope. 2012;122(7):1589–94.PubMedCrossRef
18.
Corry J, Poon W, McPhee N, Milner AD, Cruickshank D, Porceddu SV, et al. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation. J Med Imaging Radiat Oncol. 2008;52(5):503–10.PubMedCrossRef
19.
Corry J, Poon W, McPhee N, Milner AD, Cruickshank D, Porceddu SV, et al. Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. Head Neck. 2009;31(7):867–76.PubMedCrossRef
20.
Coughlan D, Frick KD. Direct medical costs of head and neck cancer in the United States: an analysis using pooled medical expenditure panel survey (MEPS) data. Value Health. 2012;15(4):A235.CrossRef
21.
Crandley EF, Wilson DD, Sim A, Blackburn N, Wang L, Rahimi AS, et al. Analysis of treatment costs and outcomes with the addition of induction chemotherapy (IC) to concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC). Int J Radiat Oncol Biol Phys. 2013;87(2):S434–5.CrossRef
22.
Diaz-de-Cerio P, Preciado J, Santaolalla F, Sanchez-Del-Rey A. Cost-minimisation and cost-effectiveness analysis comparing transoral CO(2) laser cordectomy, laryngofissure cordectomy and radiotherapy for the treatment of T1-2, N0, M0 glottic carcinoma. Eur Arch Otorhinolaryngol. 2013;270(4):1181–8.PubMedCrossRef
23.
Donato K, Leszczynski K, Fleming K. A comparative evaluation of two head and neck immobilization devices using electronic portal imaging. Br J Radiol. 2006;79(938):158–61.PubMedCrossRef
24.
Dorrian C, Ferguson J, Ah-See K, Barr C, Lalla K, van der Pol M, et al. Head and neck cancer assessment by flexible endoscopy and telemedicine. J Telemed Telecare. 2009;15(3):118–21.PubMedCrossRef
25.
Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110–20.PubMedCrossRef
26.
Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, et al. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2006;17(10):1560–7.PubMedCrossRef
27.
Gourin CG, Forastiere AA, Sanguineti G, Koch WM, Marur S, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care. Laryngoscope. 2011;121(1):85–90.PubMedCrossRef
28.
Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE. Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care. Laryngoscope. 2011;121(4):746–52.PubMedCentralPubMedCrossRef
29.
Gourin CG, Frick KD. National trends in oropharyngeal cancer surgery and the effect of surgeon and hospital volume on short-term outcomes and cost of care. Laryngoscope. 2012;122(3):543–51.PubMedCrossRef
30.
Gourin CG, Frick KD. National trends in laryngeal cancer surgery and the effect of surgeon and hospital volume on short-term outcomes and cost of care. Laryngoscope. 2012;122(1):88–94.PubMedCrossRef
31.
Greskovich JF, Gordian M, Koyfman SA, Lorenz R, Scharpf J, Khan M, et al. Improving healthcare value in patients with stage III–IV squamous cell carcinoma of head and neck (HNSCC): cost and outcome comparison of 2 arms of a randomized, phase 3 trial of definitive chemoradiation (chemoRT). Int J Radiat Oncol Biol Phys. 2013;87(2):S501.CrossRef
32.
Hennessey P, Semenov YR, Gourin CG. The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope. 2012;122(10):2199–204.PubMedCrossRef
33.
Hennessey PT, Francis HW, Gourin CG. Is there a “July effect” for head and neck cancer surgery? Laryngoscope. 2013;123(8):1889–95.PubMedCrossRef
34.
Jacobson JJ, Epstein JB, Eichmiller FC, Gibson TB, Carls GS, Vogtmann E, et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol. 2012;4(1):15.PubMedCentralPubMedCrossRef
35.
Jaspers GW, Witjes MJ, Groen HJ, Groen H, Rodiger LA, Roodenburg JL. Strategies for patients with newly diagnosed oral squamous cell carcinoma and a positive chest CT. A cohort study on the effects on treatment planning and incidence. Eur J Surg Oncol. 2011;37(3):272–7.PubMedCrossRef
36.
Jones NF, Jarrahy R, Song JI, Kaufman MR, Markowitz B. Postoperative medical complications—not microsurgical complications—negatively influence the morbidity, mortality, and true costs after microsurgical reconstruction for head and neck cancer. Plast Reconstr Surg. 2007;119(7):2053–60.PubMedCrossRef
37.
Kim K, Amonkar MM, Hogberg D, Kasteng F. Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK. Head Neck Oncol. 2011;3:47.PubMedCentralPubMedCrossRef
38.
Le Kim T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, et al. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. J Med Econ. 2012;15(4):786–95.CrossRef
39.
Kochhar A, Pronovost PJ, Gourin CG. Hospital-acquired conditions in head and neck cancer surgery. Laryngoscope. 2013;123(7):1660–9.PubMedCrossRef
40.
Kurien G, Hu J, Harris J, Seikaly H. Cost-effectiveness of positron emission tomography/computed tomography in the management of advanced head and neck cancer. J Otolaryngol Head Neck Surg. 2011;40(6):468–72.PubMed
41.
Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130(11):1269–75.PubMedCrossRef
42.
Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, et al. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2009;135(6):582–8.PubMedCrossRef
43.
Li R, Fakhry C, Koch WM, Gourin CG. The effect of tumor subsite on short-term outcomes and costs of care after oral cancer surgery. Laryngoscope. 2013;123(7):1652–9.PubMedCrossRef
44.
Maddox PT, Davies L. Trends in total laryngectomy in the era of organ preservation: a population-based study. Otolaryngol Head Neck Surg. 2012;147(1):85–90.PubMedCrossRef
45.
Menzin J, Lang KM, Friedman M, Dixon D, Marton JP, Wilson J. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health. 2005;8(2):140–8.PubMedCrossRef
46.
Nijdam W, Levendag P, Noever I, Groot CU, Agthoven M. Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiother Oncol. 2005;77(1):65–72.PubMedCrossRef
47.
Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008;113(6):1446–52.PubMedCrossRef
48.
Patil S, Kumar TN, Mohiyuddin A. Comparison of the use of single and combined antibiotics for head and neck onco-surgeries: a cost effective analysis. J Clin Diagn Res. 2011;5(4):769–71.
49.
Penel N, Lefebvre JL, Cazin JL, Clisant S, Neu JC, Dervaux B, et al. Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis. Int J Oral Maxillofac Surg. 2008;37(2):135–9.PubMedCrossRef
50.
Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012;2012.
51.
Pinto M, Uga MA. Cost of treating patients with smoking history in a specialized cancer hospital. Rev Saude Publica. 2011;45(3):575–82.PubMedCrossRef
52.
Preuss SF, Quante G, Semrau R, Mueller RP, Klussmann JP, Guntinas-Lichius O. An analysis of surgical complications, morbidity, and cost calculation in patients undergoing multimodal treatment for operable oropharyngeal carcinoma. Laryngoscope. 2007;117(1):101–5.PubMedCrossRef
53.
Pryor DI, Porceddu SV, Scuffham PA, Whitty JA, Thomas PA, Burmeister BH. Economic analysis of FDG-PET-guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma. Head Neck. 2013;35(9):1287–94.PubMedCrossRef
54.
Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, et al. Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors. J Med Econ. 2013;16(2):221–30.PubMedCrossRef
55.
Reveles IA, Kreys ED, Corral M, Zhang Y, Koeller JM. Segmented medical costs of squamous cell head and neck cancer: a pharmacoeconomic analysis using a private insurance database. Value Health. 2012;15(4):A216.CrossRef
56.
Richmon JD, Quon H, Gourin CG. The effect of transoral robotic surgery on short-term outcomes and cost of care after oropharyngeal cancer surgery. Laryngoscope. 2013.
57.
Ryu J, Nam BH, Jung YS. Clinical outcomes comparing parenteral and nasogastric tube nutrition after laryngeal and pharyngeal cancer surgery. Dysphagia. 2009;24(4):378–86.PubMedCrossRef
58.
Santamarta TR, de Villalain L, Peña I, Fernández-del Valle A, Megıas J, de Vicente JC. Abstract PP059. Comparative study of locoregional flaps and free flaps in reconstruction after resection of oral cavity cancer: a cost analysis. Oral Oncol. 2013;49:S114.CrossRef
59.
Semenov YR, Starmer HM, Gourin CG. The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope. 2012;122(9):1994–2004.PubMedCrossRef
60.
Setala L, Koskenvuori H, Gudaviciene D, Berg L, Mustonen P. Cost analysis of 109 microsurgical reconstructions and flap monitoring with microdialysis. J Reconstr Microsurg. 2009;25(9):521–6.PubMedCrossRef
61.
Sheets NC, Wheeler SB, Kohler RE, Fried DV, Brown PM, Chera BS. Costs of care in a matched pair comparison of intensity-modulated radiation therapy (IMRT) versus conventional radiation therapy (CRT) for the treatment of head and neck cancer. Am J Clin Oncol. 2013.
62.
Smeele LE, Goldstein D, Tsai V, Gullane PJ, Neligan P, Brown DH, et al. Morbidity and cost differences between free flap reconstruction and pedicled flap reconstruction in oral and oropharyngeal cancer: matched control study. J Otolaryngol. 2006;35(2):102–7.PubMedCrossRef
63.
St Guily JL, Borget I, Vainchtock A, Remy V, Takizawa C. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol. 2010;2:22.PubMedCrossRef
64.
Stalfors J, Bjorholt I, Westin T. A cost analysis of participation via personal attendance versus telemedicine at a head and neck oncology multidisciplinary team meeting. J Telemed Telecare. 2005;11(4):205–10.PubMedCrossRef
65.
Syse A, Tretli S, Kravdal O. Cancer’s impact on employment and earnings—a population-based study from Norway. J Cancer Surviv. 2008;2(3):149–58.PubMedCrossRef
66.
Tempest MJ, Thurston S, Carroll SM, Keeping ST. Preliminary results from a study of hospital costs due to treatment of head and neck cancers in England. Value Health. 2012;15(7):A418–9.
67.
Trivedi NP, Trivedi PH, Trivedi HH, et al. Abstract No. P559. Optimizing multimodality treatment for head and neck cancer in resource constrained rural India. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
68.
Uyl-de Groot CA, Senft A, de Bree R, Leemans CR, Hoekstra OS. Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients. J Nucl Med. 2010;51(2):176–82.PubMedCrossRef
69.
van Agthoven M, Heule-Dieleman HA, Knegt PP, Kaanders JH, Baatenburg de Jong RJ, Kremer B, et al. Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Eur Arch Otorhinolaryngol. 2006;263(8):729–37.PubMedCrossRef
70.
van Hooren AC, Brouwer J, de Bree R, Hoekstra OS, Leemans CR, Uyl-de Groot CA. The cost-effectiveness of 18FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur Arch Otorhinolaryngol. 2009;266(9):1441–8.PubMedCentralPubMedCrossRef
71.
Vatanasapt P, Thanaviratananich S, Ratanaanekchai T, Thepsuthammarat K. The burden of head and neck cancers in Thailand. J Med Assoc Thai. 2012;95(Suppl 7):S182–9.PubMed
72.
Waters TM, Logemann JA, Pauloski BR, Rademaker AW, Lazarus CL, Newman LA, et al. Beyond efficacy and effectiveness: conducting economic analyses during clinical trials. Dysphagia. 2004;19(2):109–19.PubMedCrossRef
73.
Watters K, O’Dwyer TP, Rowley H. Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences? J Laryngol Otol. 2004;118(9):694–9.PubMedCrossRef
74.
Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99(1):14–23.PubMedCrossRef
75.
Arshad H, Old M, Ozer E, et al. Abstract No. S348. ICU vs non ICU postoperative management of head and neck free flaps: comparative effectiveness and cost comparisons. 8th international conference on head and neck cancer, Toronto; 2012.
76.
Grewal AS, Rich JT, Gullane PJ, et al. Abstract No. P558. Cost analysis for surgical treatment of mandibular osteoradionecrosis. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
77.
Hammoudi K, Pinlong E, Kim S. Abstract No. P074. Comparative study between transoral robotic surgery and conventional surgery for treatment of squamous cell carcinoma of the upper aerodigestive tract. American Head & Neck Society Annual Meeting, Orlando; 2013.
78.
Hollenbeak CS, Mackley H, Koch W, et al. Abstract No. S170. Costs associated with head and neck cancer in the elderly. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
79.
O’Connor R, Pezier TF, McGurk M. Abstract No. P106. Cost comparison of elective neck dissection vs sentinel lymph node biopsy in early oral squamous cell carcinoma. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
80.
Pearce AM, Timmons A, Hanly P, et al. Abstract No. PCN146. Workforce participation and productivity losses after head and neck cancer. International Society for Pharmacoeconomics and Outcomes Research 16th annual European Congress, Dublin; 2013.
81.
Razfar A, Grogan T, Lee S, et al. Abstract No. P068. Medicare cost implications in treatment of T1-T3 laryngeal carcinoma. American Head and Neck Society Annual Meeting, Orlando; 2013.
82.
Razfar A, Mundi J, Grogan T, et al. Abstract No. S003. IMRT increases Medicare cost in head and neck cancer patients: A SEER-based study. 8th International Conference on Head and Neck Cancer, Toronto; 2012.
83.
84.
85.
Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.PubMedCentralPubMedCrossRef
86.
Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst. 2008;100(24):1763–70.PubMedCentralPubMedCrossRef
87.
Serrier H, Sultan-Taieb H, Luce D, Bejean S. Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France. Eur J Health Econ. 2013.
88.
89.
90.
91.
Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyogg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med Technol. 2010;38(1):6–17.PubMedCrossRef
92.
von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238(2):405–22.CrossRef
93.
Trivedi NP, Trivedi P, Trivedi H, Trivedi S, Trivedi N. Optimizing multimodality treatment for head and neck cancer in rural India. Indian J Cancer. 2012;49(2):225–9.PubMedCrossRef
94.
Blackwell KE, Azizzadeh B, Ayala C, Rawnsley JD. Octogenarian free flap reconstruction: complications and cost of therapy. Otolaryngology Head Neck Surg. 2002;126(3):301–6.CrossRef
95.
Lee JM, Turini M, Botteman MF, Stephens JM, Pashos CL. Economic burden of head and neck cancer. A literature review. Eur J Health Econ. 2004;5(1):70–80.PubMedCrossRef
96.
Himmel M, Hartmann M, Guntinas-Lichius O. Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis. Oncology. 2013;84(6):336–41.PubMedCrossRef
97.
Cuckler GA, Sisko AM, Keehan SP, Smith SD, Madison AJ, Poisal JA, et al. National health expenditure projections, 2012–2022: slow growth until coverage expands and economy improves. Health Aff (Millwood). 2013;32(10):1820–31.CrossRef
98.
Metadata
Title
The Economic Burden of Head and Neck Cancer: A Systematic Literature Review
Authors
Erika Wissinger
Ingolf Griebsch
Juliane Lungershausen
Talia Foster
Chris L. Pashos
Publication date
01-09-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-014-0169-3

Other articles of this Issue 9/2014

PharmacoEconomics 9/2014 Go to the issue

Commentary

Hospital-Based Health Technology Assessment: Insights from New Zealand

Review Article

Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges

Original Research Article

Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada

Review Article

HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes

Systematic Review

Discrete Choice Experiments in Health Economics: A Review of the Literature

Leading Article

Hospital-Based Health Technology Assessment: Developments to Date